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HISTORY
• Galactosemia first described in detail by Howard Mason
and Mary Turner in 1935.
• In the 1950s, Dr. Luis Leloir and colleagues worked out the
pathway for converting galactose to glucose via sugar
nucleotides. In 1970, Dr. Leloir won the Nobel Prize for his
work on sugar nucleotides.
• In 1988, the gene that codes for galactose-1-phosphate
uridylyltransferase (GALT), an enzyme crucial for galactose
metabolism via the Leloir pathway, was identified.




• Classical galactosemia (Type I, GALT deficiency) affects about 1 in 16,000-48,000 infants globally.
• Types II and III galactosemia are much more rare than classical galactosemia; they result from 
deficiencies in Leloir pathway enzymes other than GALT.
Provenance
• Galactosemia has no specific area of origin, but it is found in at least 24 populations of ethnic 
groups in 15 countries worldwide.
• Galactosemia is most common in Irish and African populations
AUTOSOMAL RECESSIVE INHERITANCE
HNEkidshealth. “Autosomal Recessive Inheritance - Genetics.” Youtube, Youtube, 30 Mar. 2015, https://youtu.be/Nv6qUsKYodA?t=90
GENETICS
• Classical galactosemia is autosomal recessive,
requiring two copies of the defective GALT gene.
• It is estimated that 1 in 125 people are carriers for
the defective GALT gene.
• There are different mutations in the GALT gene,
with varying levels of severity. Sixty percent of
recorded cases are due to the most common
variants of Galactosemia in the populations that
were studied. Digital image retrieved Oct. 13, 2019 from 
https://www.geneticsupport.org/genetics-101/inheritance-patterns/autosomal-recessive/
CLASSICAL GALACTOSEMIA (TYPE I)
• Inactive galactose-1-phosphate uridylyl transferase (GALT) enzyme.
- GALT is used to process galactose, a sugar component in
lactose, which is found in products like milk.
• GALT enzyme deficiency results in a ripple effect, causing the build
up of different products in the blood and tissues, resulting in the
associated health issues.
- Galactitol is one product that accumulates as a result of the
GALT deficiency, resulting in the formation of cataracts.












• Delayed speech development
• Movement disorders
• Ovarian failure in females 
Digital image retrieved Nov. 1, 2019 from
https://www.epainassist.com/genetic-disorders/galactosemia
DIAGNOSIS
Goal: Measure GALT activity levels and buildup of reducing sugars
Prenatal (before birth):
• Amniocentesis (test sample from amniotic fluid)
• Chorionic Villus sampling (test sample from placental tissue)
Neonatal (immediately after birth):
• Blood test from infant heel
- Supporting tests: urine test for reducing sugars and 
molecular genetic screening




• If diagnosed early and galactose-free diet is maintained, individuals can have a normal 
lifespan.
• However, individuals are still at risk for the development of many long-term symptoms 
and complications.
• If treatment is not prompt and consistent, severe complications and irreversible 
intellectual disability may occur.
THERAPY
• Other types of therapy:
• Speech therapy and Individualized education
• Physical Therapy*Currently, diet is the only treatment for galactosemia
Digital image retrieved Nov. 10, 2019 from
https://foodstruct.com/list/foods-high-in-galactose
Diet*
• Immediate switch to soy-containing formula




- Other dairy products
• Omit medications containing:
- Whey
- Casein
• Supplement nutrients lost due to diet changes:
- Calcium and Vitamin D
AVAILABLE SUPPORT
Galactosemia Association of Midwest America
• Non-profit organization based in Wilmington, Illinois aimed at supporting families in the US mid-
west who have children affected by galactosemia
• Organizes fundraisers for research and scholarships as well as socials to help connect and
educate affected families
Galactosemia Foundation
• A nationwide organization that provides
resources for affected families including
dietary guidelines and a network of
families, clinicians, and researchers
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